@article{Земляніцина_2021, title={THE ROLE OF RESISTIN, IL-1β, IL-6 AND CERULOPL ASMIN IN THE PATHOGENESIS OF NON-ALCOHOLIC FAT T Y LIVER DISE ASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS}, volume={76}, url={https://www.jpep.endocrinology.org.ua/index.php/1/article/view/612}, DOI={10.21856/j-PEP.2021.2.04}, abstractNote={<p>To determine the role of resistin, IL-1β, IL-6 and ceruloplasmin in the development of NAFLD and cardiovascular complications in patients with type 2 diabetes, 82 patients with type 2 diabetes with NAFLD were examined. All patients were divided into groups depending on the degree of liver damage: group 1 (stage of steatosis) — included 22 patients, group 2 (stage of steatohepatitis, NASH) — 40 patients, group 3 (stage of fibrosis) — 20 patients. The control group included 7 patients with type 2 diabetes without liver damage.<br>Based on the stusy results analysis, it can be stated that adipokin resistin should be considered as one of the factors in the pathogenesis of NAFLD in patients with type 2 diabetes, namely as a marker of inflammatory changes in the liver in this category of patients. Further development of the disease at the stage of fibrosis is characterized by a slight decrease in the serum resistin concentration, which may indicate a decrease in inflammatory processes against the background of the development of fibrotic changes. It is at the stage of fibrosis that resistin is unidirectionally correlated with some lipid fractions, which confirms its role in atherogenesis and in the risk of developing cardiovascular complications of diabetes. With the development of NAFLD in patients with type 2 diabetes, the level of pro-inflammatory interleukins IL-1β and IL-6 increases<br>already at the stage of NAS. It reflects inflammatory changes in the liver of these patients. Further insignificant increase in the content of interleukins IL-1β and IL-6 in the serum of patients may indicate the preservation of a high level of inflammation both at the stage of steatohepatitis and in the future, in the formation of fibrosis.<br>We found no significant differences between ceruloplasmin levels in patients with type 2 diabetes with various stages of NAFLD and in the absence of liver damage</p>}, number={2}, journal={Problems of Endocrine Pathology}, author={Земляніцина, О. В.}, year={2021}, month={Jun.}, pages={27-34} }